340B PATIENTS Act of 2025
- Bill Number
- H.R. 4581
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-07-22: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-04-23T08:07:15Z
AI-Generated Summary
Purpose of the Legislation
The 340B PATIENTS Act of 2025 aims to clarify and strengthen the 340B drug discount program under the Public Health Service Act. This program requires drug manufacturers to provide outpatient drugs at discounted prices (known as "ceiling prices") to eligible healthcare providers, called "covered entities," such as safety-net hospitals and clinics. The bill ensures these discounts apply without restrictions based on how or where the drugs are dispensed, including through partnerships with outside pharmacies (contract pharmacies). It addresses manufacturer practices that have limited access to these discounts, promoting broader use of savings to serve more patients, especially those with chronic or serious conditions.
Key Provisions
- Discount Requirements: Manufacturers must offer ceiling prices for drugs purchased by covered entities, regardless of the dispensing method (e.g., in-house or via contract pharmacies) or location (e.g., specialty or mail-order pharmacies).
- Prohibition on Manufacturer Conditions: Manufacturers cannot impose restrictions on covered entities' purchases or use of discounted drugs, such as limits on delivery, purchase mechanisms, dispensing locations, or requirements for data submission or compliance assurances. Exceptions apply only to standard business practices or Secretary-approved conditions that do not undermine the program's goals.
- Contract Pharmacies: Covered entities can partner with pharmacies to dispense discounted drugs to their patients, and all program rules apply to these arrangements. This helps entities extend resources for patient care.
- Enforcement and Penalties:
- Adds civil monetary penalties up to $2,000,000 per day for intentional violations (other than overcharges), based on factors like violation severity, affected drugs, and impacted entities.
- Requires the Secretary of Health and Human Services (HHS) to issue regulations within 180 days for penalty standards and a process for covered entities to report violations.
- Findings Support: The bill includes congressional findings highlighting the program's role in stretching resources, serving vulnerable communities, and reducing Medicare costs through lower drug price increases.
Significant Changes to Existing Law
- Amends Section 340B(a) of the Public Health Service Act to explicitly state that discounts are not limited by dispensing manner or location and to ban certain manufacturer-imposed conditions, which were not previously detailed in the law.
- Adds a new subsection (a)(11) affirming contract pharmacy use, codifying practices that have evolved since the program's start but faced recent manufacturer challenges.
- Enhances Section 340B(d) by introducing daily penalties for non-overcharge violations and a formal claims process for covered entities, expanding beyond existing overcharge remedies. Previously, enforcement focused mainly on overcharges with refunds and potential agreement termination.
Potential Impacts
- On Government Agencies: HHS gains clearer authority to regulate and enforce the program, including new rulemaking deadlines, which could increase administrative workload but improve compliance oversight. It may indirectly support Medicare savings by maintaining the program's effectiveness in curbing drug price inflation.
- On Citizens: Low-income and underserved patients, particularly those needing specialty drugs for conditions like cancer or multiple sclerosis, could gain better access to affordable medications through expanded contract pharmacy options, potentially improving care and reducing out-of-pocket costs.
- On International Relations: No direct impacts, as the bill focuses on domestic U.S. healthcare pricing and provider access.
- Overall, the changes could enhance program efficiency, allowing covered entities to serve more patients without new funding, but may face implementation challenges if disputes arise.
Main Stakeholders Affected
- Covered Entities: Safety-net hospitals, clinics, and health centers that rely on 340B discounts to fund community services; they benefit from unrestricted access and easier enforcement.
- Patients: Underserved individuals, including those with chronic illnesses, who receive care from covered entities; improved drug access could expand treatment options.
- Drug Manufacturers: Required to provide discounts without restrictions, potentially reducing their revenue from full-price sales but facing penalties for non-compliance.
- Contract Pharmacies: Pharmacies partnering with covered entities; the bill supports their role in dispensing, especially for specialty drugs not available locally.
- HHS and Regulators: Tasked with new enforcement rules and penalty assessments, affecting oversight of the program.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens statutory clarity to prevent manufacturer lawsuits or restrictions, potentially reducing litigation over contract pharmacy use (e.g., past disputes where manufacturers limited shipments). The bill's prohibitions on conditions could invite challenges under contract law or administrative procedure, but it empowers HHS to approve exceptions, balancing flexibility.
- Constitutional: No direct challenges anticipated; it aligns with Congress's authority to regulate interstate commerce and healthcare under the Commerce Clause, without implicating free speech, due process, or other rights.
- Political: Reinforces bipartisan support for affordable drug access in underserved areas, countering pharmaceutical industry pushback on 340B expansion. It may influence ongoing debates on drug pricing reforms, emphasizing patient-centered use of savings over manufacturer profits, but could polarize along industry vs. provider lines in future appropriations or reauthorizations.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Matsui, Doris O. [D-CA-7]
Cosponsors (19)
Rep. Trahan, Lori [D-MA-3], Rep. Tonko, Paul [D-NY-20], Rep. Davids, Sharice [D-KS-3], Rep. McCollum, Betty [D-MN-4], Rep. Thanedar, Shri [D-MI-13], Rep. Tlaib, Rashida [D-MI-12], Rep. Frost, Maxwell [D-FL-10], Rep. Castor, Kathy [D-FL-14], Rep. Escobar, Veronica [D-TX-16], Rep. McGovern, James P. [D-MA-2], Rep. Krishnamoorthi, Raja [D-IL-8], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Jayapal, Pramila [D-WA-7], Rep. Tokuda, Jill N. [D-HI-2], Rep. Lynch, Stephen F. [D-MA-8], Rep. Cleaver, Emanuel [D-MO-5], Rep. Moore, Gwen [D-WI-4], Rep. Torres, Ritchie [D-NY-15], Rep. Vindman, Eugene Simon [D-VA-7]
Recent Actions
- 2025-07-22: Referred to the House Committee on Energy and Commerce.
- 2025-07-22: Introduced in House
- 2025-07-22: Introduced in House
Bill Versions
- 340B Pharmaceutical Access To Invest in Essential, Needed Treatments & Support Act of 2025 — issued 2025-07-22 — PDF (10 pages)